Pharmafile Logo

News and Press Releases

Leqembi ▼ (lecanemab) proposed Marketing Authorisation Variation for monthly intravenous maintenance dosing for the treatment of early Alzheimer’s disease in the UK is validated for evaluation by the MHRA

Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment The...

Category: Other, Pharmaceutical
Posted: April 30, 2025

Eisai
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

ESCMID Global 2025: Shionogi presents real-world data demonstrating better clinical outcomes when Fetcroja / Fetroja (cefiderocol) is used as empiric or documented therapy as compared to salvage therapy for the treatment of Gram-negative bacterial infections

Data from five European countries demonstrates the effectiveness of cefiderocol against Gram-negative pathogens considered as high or critical priorities by the WHO, including high rates of clinical cure and day...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 8, 2025

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia

19 December 2024 – Tokyo, Japan and Cambridge, UK, – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares –...

Category: Drug Delivery, Drug Discovery
Posted: December 19, 2024

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Inceptua Group Expands Early Access Programme to Latin America

15 May 2024 -- Luxembourg -- Inceptua, a global pharmaceutical service company, announces an expansion of an Early Access Programme for cefiderocol for eligible patients in Argentina, Chile, Colombia, Guatemala,...

Category: Clinical Trials, Drug Delivery, Logistics
Posted: May 15, 2024

Inceptua
Info@inceptua.com
2 place de Paris 2314 Luxembourg

Positive Results from Phase 3 Clinical Trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan

26 February 2024 -- Osaka, Japan -- Shionogi & Co announces the submission of a marketing approval application for the digital therapeutic app SDT-001, for commercialisation and sale in Japan,...

Category: Clinical Trials
Posted: February 27, 2024

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023

New exploratory analysis of phase 3 SCORPIO-SR study data in Asia suggests that ensitrelvir may reduce the risk of persistent and new late-onset symptoms associated with long COVID-19 over one...

Category: Clinical Trials
Posted: September 20, 2023

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK